- Second-quarter revenue increased 10% year over year to $1.217 billion (9% organic growth).
- Companion Animal Group diagnostics recurring revenue grew 11% as reported (10% organic).
- Diluted EPS increased 18% to $4.27, while operating margin expanded to 35.0%.
- IDEXX inVue Dx™ installed base surpassed 9,000 instruments, including more than 1,600 placements during the quarter.
- IDEXX increased its 2026 EPS guidance to $14.69–$14.94 and raised the midpoint of its full-year revenue outlook.
IDEXX Laboratories reported second-quarter 2026 financial results highlighted by continued growth in companion animal diagnostics and higher profitability, prompting the company to increase its earnings outlook for the full year.
Diagnostics growth drives results
Revenue for the quarter reached $1.217 billion, an increase of 10% compared with the second quarter of 2025, or 9% on an organic basis. Companion Animal Group diagnostics recurring revenue grew 11% as reported and 10% organically, supported by higher testing utilization, commercial execution and continued adoption of IDEXX diagnostic platforms. Water revenues increased 15%, while Livestock, Poultry and Dairy revenues rose 11%.
Margins expand as outlook improves
Diluted earnings per share increased 18% year over year to $4.27, while operating margin expanded to 35.0%. Gross margin improved to 64.0%, and the installed base of IDEXX inVue Dx analyzers surpassed 9,000 instruments, including more than 1,600 placements during the quarter.
For 2026, IDEXX now expects revenue of $4.70 billion to $4.745 billion and diluted EPS of $14.69 to $14.94. The company also projects a full-year operating margin of 32.3% to 32.5%.
Information sourced from the company’s earnings release.
